Evidence map›Paper›PMID 31829224›Full record

ArticleBMC health services research2019

Prediction of health care expenditure increase: how does pharmacotherapy contribute?

Annika M Jödicke, Urs Zellweger, Ivan T Tomka, Thomas Neuer, Ivanka Curkovic, Malgorzata Roos, Gerd A Kullak-Ublick, Hayk Sargsyan, Marco Egbring

Abstract read
In one paragraph

Article in BMC health services research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Observational
  2. Article
  3. Identifying diseases in claims data using a machine learning approach - a case from Switzerland.Archives of public health = Archives belges de sante publique · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The application of artificial intelligence in health financing: a scoping review.Cost effectiveness and resource allocation : C/E · 2023
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annika M JödickeDepartment of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-0000-0110
Urs ZellwegerDepartment of Client Services & Claims, Helsana Group, Zurich, Switzerland.
Ivan T TomkaDepartment of Client Services & Claims, Helsana Group, Zurich, Switzerland.
Thomas NeuerEPha.ch AG, Data Science in Healthcare, Zurich, Switzerland.
Ivanka CurkovicDepartment of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Malgorzata RoosEBPI, Department of Biostatistics, University of Zurich, Zurich, Switzerland.
Gerd A Kullak-UblickDepartment of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Hayk SargsyanEPha.ch AG, Data Science in Healthcare, Zurich, Switzerland.
Marco EgbringDepartment of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. marco.egbring@usz.ch.ORCID http://orcid.org/0000-0002-4201-1483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRising health care costs are a major public health issue. Thus, accurately predicting future costs and understanding which factors contribute to increases in health care expenditures are important. The objective of this project was to predict patients healthcare costs development in the subsequent year and to identify factors contributing to this prediction, with a particular focus on the role of pharmacotherapy.

methodsWe used 2014-2015 Swiss health insurance claims data on 373'264 adult patients to classify individuals' changes in health care costs. We performed extensive feature generation and developed predictive models using logistic regression, boosted decision trees and neural networks. Based on the decision tree model, we performed a detailed feature importance analysis and subgroup analysis, with an emphasis on drug classes.

resultsThe boosted decision tree model achieved an overall accuracy of 67.6% and an area under the curve-score of 0.74; the neural network and logistic regression models performed 0.4 and 1.9% worse, respectively. Feature engineering played a key role in capturing temporal patterns in the data. The number of features was reduced from 747 to 36 with only a 0.5% loss in the accuracy. In addition to hospitalisation and outpatient physician visits, 6 drug classes and the mode of drug administration were among the most important features. Patient subgroups with a high probability of increase (up to 88%) and decrease (up to 92%) were identified.

conclusionsPharmacotherapy provides important information for predicting cost increases in the total population. Moreover, its relative importance increases in combination with other features, including health care utilisation.

Indexed as

AgedDrug TherapyFemaleHealth ExpendituresHumansInsurance Claim ReviewInsurance, HealthMaleMiddle AgedSwitzerlandBoosted decision treeClaims dataHealth care costsHealth care utilisationMachine learningNeural networkPharmacology

Identifiers

PMID31829224
PMCPMC6907182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.